FAIR PRICING FOR MEDICINES

Motion text

That this House notes with deep concern that the issue of excessively high medicine prices and systemic lack of transparency in the Research & Development (R&D) system is a global crisis; further notes that the second Fair Pricing Forum will take place in April 2019 presenting a critical opportunity for stakeholders to discuss how to respond to arbitrary priced medicines and define what is a fair price for medicines; acknowledges that different people will have different understandings of what is fair price; believes that a definition of fairness must prioritise access to medicines and transparency of R&D outlays and price-setting; and calls on the UK Government and other World Health Organisation member states to support Italy’s draft resolution entitled, Improving the transparency of markets for drugs, vaccines and other health-related technologies that will be discussed at the 72nd World Health Assembly.

The first 6 Members who have signed to support the motion are the sponsors. The primary sponsor is generally the person who tabled the motion and has responsibility for it. The date shown is when the Member signed the motion.

EDM (Early Day Motion) 2272: tabled on 08 April 2019

Motion text

Signatures (36)